Navigation Links
Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
Date:1/20/2009

erning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business", "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them." and "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations". Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Volcano Corporation (Nasdaq: ... therapy guidance tools - including Fractional Flow Reserve ... Optical Coherence Tomography (OCT) - designed to enhance ... vascular disease, announced today the placement of over ... family of consoles was first launched in April ...
(Date:12/15/2009)... Fenwal Inc., a global leader focused on improving blood ... commitment to provide blood centers with Alyx® system supplies ... lawsuit filed yesterday against Fenwal by Haemonetics Corporation ( ... is an advanced medical instrument used worldwide to collect ... in about 30 minutes. ,, Fenwal will ...
(Date:12/15/2009)... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced ... dividend payment of $1.67 per share to all stockholders ... With this payment, distributions to stockholders for the ... In January 2010, the Company will make a ... 2009 cash distributions and the allocation between dividend income ...
Breaking Medicine Technology:Volcano Announces Installed Base Growth Milestone 2Volcano Announces Installed Base Growth Milestone 3Volcano Announces Installed Base Growth Milestone 4Volcano Announces Installed Base Growth Milestone 5Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3PDL BioPharma Completes December 15 Special Dividend Payment 2Pregnancy Complication May Be Linked to Thyroid Problems 61608 1Terumo Heart Inc Wins Top Healthcare Category Honors at AnnArbor com 26apos 3Bs 5th Annual 26amp 3B 238216 3BDeals Of The Year 26apos 3B Award Cere 61603 1Terumo Heart Inc Wins Top Healthcare Category Honors at AnnArbor com 26apos 3Bs 5th Annual 26amp 3B 238216 3BDeals Of The Year 26apos 3B Award Cere 61603 2Terumo Heart Inc Wins Top Healthcare Category Honors at AnnArbor com 26apos 3Bs 5th Annual 26amp 3B 238216 3BDeals Of The Year 26apos 3B Award Cere 61603 3Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction Inc 61599 1Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction Inc 61599 2Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction Inc 61599 3
... 25, 2007 - XenoPort, Inc.,(Nasdaq: XNPT) today announced ... XP13512 for the treatment of symptoms of primary,restless ... to placebo on both of the,co-primary endpoints of ... are very encouraging and represent a major,advance for ...
... WIRE)--Apr 25, 2007 - DuoCort AB,today announced that ... 5 mg and,20 mg dual release hydrocortisone tablets ... European Congress of Endocrinology on,April 30 in Budapest. ... new hydrocortisone tablets in healthy,volunteers., The Phase I ...
Other Medicine Technology:XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 2XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 3XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 4XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 5DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology 2
(Date:12/16/2009)... are uninsured, government report finds , , WEDNESDAY, Dec. 16 ... this year, 45.4 million Americans of all ages -- ... health insurance, according to new National Health Interview Survey ... percent) people of all ages had been uninsured for ... interview, and 31.9 million (10.6 percent) had been uninsured ...
(Date:12/16/2009)... -- OrthoAccel Technologies, Inc., developers of the ... to enhance orthodontics, announced Alison Davies as its ... Ms. Davies has spent the last fourteen years ... most recently for nine years as a senior ... Invisalign . ,, (Logo: ...
(Date:12/16/2009)... 16 New research published online, ... in pistachios, and molecules present in pistachios, ... decreases levels of an inflammatory marker known ... 2). Inflammation is a complex biological response ... irritants, and it underlies functional changes associated ...
(Date:12/16/2009)... Quantros, Inc., a leading provider of safety and ... healthcare industry, announces the creation of a new ... industry veteran Michael Tulloch, MBA, as Director of ... company,s new Marlborough, MA office. ,, "The expansion ... Tulloch. "Quantros has been developing software for the ...
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
Breaking Medicine News(10 mins):Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2
... Colorectal cancer is one of the deadliest but most ... American Gastroenterological Association (AGA) Institute supports clinically proven technologies ... for the disease. , At the American College ... presented results from the National CT Colonography Trial. This ...
... HIS and EMR solutions, BOTHELL, Wash., Oct. ... a global leader in advanced cardiac monitoring,and defibrillation ... RMS(R) 3.0. This significant advance to the trusted ... upgrades and,workflow advancements to enable the best possible ...
... Meet Isabel, a busy,active 50-year-old Hispanic woman who has ... son; and enjoys being a grandmother to her,daughter,s son. ... her wrist, and her doctor tells her she has ... is typical of many women like her. To ...
... Health Information Services Portfolio with ... Active, Outsourced File Room Solutions, BOSTON, Oct. 2 ... in information protection and storage,services, today announced its acquisition of ... and the industry leading provider of,outsourced file room solutions for ...
... for a loved one with dementia, TUCSON, Ariz., ... a new book that aims to ease the challenges ... and,Families are Still Asking WHY?, author Jim Greenwood, whose ... and useful,advice on how to best care for a ...
... October 2, 2007 Do young adults learn behaviors ... issue of the American Journal of Preventive Medicine, researchers ... relationship between young adults (age 18-25) observing smoking in ... found that more exposure to smoking in movies was ...
Other Medicine News:Health News:Virtual colonoscopy -- a new technology for colorectal cancer screening? 2Health News:Cardiac Science Releases New Cardiac Rehabilitation System 2Health News:Cardiac Science Releases New Cardiac Rehabilitation System 3Health News:Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis 2Health News:Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis 3Health News:Iron Mountain Acquires RMS Services - USA, Inc. 2Health News:Iron Mountain Acquires RMS Services - USA, Inc. 3Health News:Alzheimer's Caregivers Get Sage Advice 2